This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Xenoport's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Xenoport, Inc. (XNPT)

Q2 2012 Results Earnings Call

August 7, 2012 5:00 PM ET


Jackie Cossmon – Investor Relations

Ron Barrett – Chief Executive Officer

Bill Harris – Vice President, Finance and CFO

Vince Angotti – Executive Vice President and COO


Ravi Mehrotra – Credit Suisse

Michael Yee – RBC Capital Markets

Brian Abrahams – Wells Fargo Securities

Eric Schmidt – Cowen and Company

Juan Sanchez – Ladenburg Thalman & Company & Company

David Friedman – Morgan Stanley



Good afternoon. My name is [Temra], and I will be your conference operator today. At this time, I would like to welcome everyone to the XenoPort Second Quarter Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. (Operator Instructions)

Thank you. Ms. Cossmon. You may begin your conference.

Jackie Cossmon

Thank you, [Temra]. Good afternoon and thank you for joining us on the call. Here with me today are Ron Barrett, our Chief Executive Officer; Bill Harris, our Vice President of Finance and Chief Financial Officer; and Vince Angotti, our Executive Vice President and Chief Operating Officer.

Before we begin our discussion of today's news, I would like to note that the information to be discussed on this conference call and webcast, including answers to questions asked during this call will include forward-looking statements that involve risks and uncertainties, including statements related to the therapeutic and commercial potential of our product candidates, future sales of and promotional activities for gabapentin enacarbil, FDA and other regulatory authority discussions, regulatory processes and the timing of regulatory filings and actions, our current and future clinical development programs and clinical trials, the release of additional clinical trial data and the timing thereof, our clinical development efforts, potential advantages of our product candidates, our dependence on collaborative partners and matters related to our dispute with GSK.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs